Journal of Clinical Oncology, Vol 16, 2188-2194, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report

SM Chang, JG Kuhn, J Rizzo, HI Robins, SC Schold Jr, AM Spence, MS Berger, MP Mehta, ME Bozik, I Pollack, M Gilbert, D Fulton, C Rankin, M Malec and MD Prados
Department of Neurosurgery, University of California, San Francisco, USA. changs@neuro.ucsf.edu

PURPOSE: To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. PATIENTS AND METHODS: Patients were stratified by starting dose of paclitaxel and concurrent anticonvulsant (AC) use and were treated in cohorts of three patients. The starting dose was 240 mg/m2 administered intravenously with escalations of 30 mg/m2 until the MTD was established. Pharmacokinetic data were obtained for each patient for the first infusion. Tumor response was assessed at 6-week intervals and treatment was continued until documented tumor progression, unacceptable toxicity, or a total of 12 paclitaxel infusions. RESULTS: From April 1995 to December 1996, 34 patients were treated; 27 patients in the AC group and seven patients in the non-AC group. The MTD for patients who received ACs was established at 360 mg/m2 and the dose- limiting toxicity (DLT) was central neurotoxicity, characterized as transient encephalopathy and seizures. In contrast, the MTD for patients who did not receive ACs was 240 mg/m2, and myelosuppression, gastrointestinal toxicity, and fatigue were the DLTs. Pharmacokinetic data confirmed that the plasma drug levels and clearance rates were similar for patients in both groups at the respective dose levels that produced DLTs. CONCLUSION: The pharmacokinetics of paclitaxel are altered by ACs, and significantly larger doses of the drug can be administered to patients with brain tumors on AC therapy. The toxicity profile is different for patients on AC therapy treated at these higher doses. A phase II study has been initiated that uses a dose of 330 mg/m2 for patients on AC therapy and 210 mg/m2 for patients not on AC therapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium Neuro-oncol, August 1, 2008; 10(4): 631 - 642. [Abstract] [Full Text] [PDF]

				R. L. Fine, J. Chen, C. Balmaceda, J. N. Bruce, M. Huang, M. Desai, M. B. Sisti, G. M. McKhann, R. R. Goodman, J. S. Bertino Jr., et al. Randomized study of Paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin. Cancer Res., October 1, 2006; 12(19): 5770 - 5776. [Abstract] [Full Text] [PDF]

				T. F. Cloughesy, P. Y. Wen, H. I. Robins, S. M. Chang, M. D. Groves, K. L. Fink, L. Junck, D. Schiff, L. Abrey, M. R. Gilbert, et al. Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study J. Clin. Oncol., August 1, 2006; 24(22): 3651 - 3656. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]

				T. F. Cloughesy, J. Kuhn, H. I. Robins, L. Abrey, P. Wen, K. Fink, F. S. Lieberman, M. Mehta, S. Chang, A. Yung, et al. Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study J. Clin. Oncol., September 20, 2005; 23(27): 6647 - 6656. [Abstract] [Full Text] [PDF]

				G. Singh, P. H. Driever, and J. W. Sander Cancer risk in people with epilepsy: the role of antiepileptic drugs Brain, January 1, 2005; 128(1): 7 - 17. [Abstract] [Full Text] [PDF]

				C. D. Katsetos, A. Legido, E. Perentes, and S. J. Mork Class III {beta}-Tubulin Isotype: A Key Cytoskeletal Protein at the Crossroads of Developmental Neurobiology and Tumor Neuropathology J Child Neurol, December 1, 2003; 18(12): 851 - 866. [Abstract] [PDF]

				M. J. van den Bent, W. Grisold, D. Frappaz, R. Stupp, J. P. Desir, T. Lesimple, C. Dittrich, M. J. A. de Jonge, A. Brandes, M. Frenay, et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme Ann. Onc., December 1, 2003; 14(12): 1732 - 1734. [Abstract] [Full Text] [PDF]

				R. H. J. Mathijssen, J. Verweij, P. de Bruijn, W. J. Loos, and A. Sparreboom Effects of St. John's Wort on Irinotecan Metabolism J Natl Cancer Inst, August 21, 2002; 94(16): 1247 - 1249. [Abstract] [Full Text] [PDF]

				C. D. Britten, S. D. Baker, L. J. Denis, T. Johnson, R. Drengler, L. L. Siu, K. Duchin, J. Kuhn, and E. K. Rowinsky Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel Clin. Cancer Res., September 1, 2000; 6(9): 3459 - 3468. [Abstract] [Full Text]

				D. Frame Introduction to taxane pharmacokinetics and pharmacodynamics Journal of Oncology Pharmacy Practice, September 1, 2000; 6(3_suppl): S23 - S27. [Abstract] [PDF]

				M. J. Glantz, B. F. Cole, P. A. Forsyth, L. D. Recht, P. Y. Wen, M. C. Chamberlain, S. A. Grossman, and J. G. Cairncross Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, May 23, 2000; 54(10): 1886 - 1893. [Full Text] [PDF]

				M. A. Villalona-Calero, T. Petit, J. Kuhn, P. Cobb, M. Kraynak, S. G. Eckhardt, R. Drengler, C. Simmons, P. Santabarbara, D. D. Von Hoff, et al. A Phase I and Pharmacological Study of Protracted Infusions of Crisnatol Mesylate in Patients with Solid Malignancies Clin. Cancer Res., November 1, 1999; 5(11): 3369 - 3378. [Abstract] [Full Text] [PDF]

				S. H. Tseng, M. S. Bobola, M. S. Berger, and J. R. Silber Characterization of paclitaxel (Taxol(R)) sensitivity in human glioma- and medulloblastoma-derived cell lines Neuro-oncol, April 1, 1999; 1(2): 101 - 108. [Abstract] [PDF]

				E. K. Rowinsky On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486. [Full Text] [PDF]

				M. H. Woo, M. V. Relling, D. S. Sonnichsen, G. K. Rivera, C. B. Pratt, C.-H. Pui, W. E. Evans, and A. S. Pappo Phase I Targeted Systemic Exposure Study of Paclitaxel in Children with Refractory Acute Leukemias Clin. Cancer Res., March 1, 1999; 5(3): 543 - 549. [Abstract] [Full Text] [PDF]